JP2004536847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536847A5 JP2004536847A5 JP2003511808A JP2003511808A JP2004536847A5 JP 2004536847 A5 JP2004536847 A5 JP 2004536847A5 JP 2003511808 A JP2003511808 A JP 2003511808A JP 2003511808 A JP2003511808 A JP 2003511808A JP 2004536847 A5 JP2004536847 A5 JP 2004536847A5
- Authority
- JP
- Japan
- Prior art keywords
- eye
- pharmaceutical composition
- tubulin binding
- neovascularization
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 47
- 102000004243 Tubulin Human genes 0.000 claims 30
- 108090000704 Tubulin Proteins 0.000 claims 30
- 239000011230 binding agent Substances 0.000 claims 30
- 239000007924 injection Substances 0.000 claims 26
- 238000002347 injection Methods 0.000 claims 26
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical group C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 claims 15
- 229960005537 combretastatin A-4 Drugs 0.000 claims 15
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 claims 15
- 208000030533 eye disease Diseases 0.000 claims 11
- 206010029113 Neovascularisation Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 208000024519 eye neoplasm Diseases 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 239000002552 dosage form Substances 0.000 claims 9
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 8
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 8
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 8
- 201000000582 Retinoblastoma Diseases 0.000 claims 8
- 239000003889 eye drop Substances 0.000 claims 8
- 229940012356 eye drops Drugs 0.000 claims 8
- 239000007943 implant Substances 0.000 claims 8
- 201000008106 ocular cancer Diseases 0.000 claims 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 7
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 7
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 201000000159 corneal neovascularization Diseases 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 238000007910 systemic administration Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000003885 eye ointment Substances 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000011505 plaster Substances 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 208000022873 Ocular disease Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 210000001742 aqueous humor Anatomy 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229960005527 combretastatin A-4 phosphate Drugs 0.000 claims 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 238000004925 denaturation Methods 0.000 claims 1
- 230000036425 denaturation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38622701P | 2001-07-13 | 2001-07-13 | |
| US37755602P | 2002-05-03 | 2002-05-03 | |
| US37784702P | 2002-05-03 | 2002-05-03 | |
| US37784502P | 2002-05-03 | 2002-05-03 | |
| PCT/US2002/022449 WO2003006002A1 (en) | 2001-07-13 | 2002-07-15 | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009063664A Division JP2009132738A (ja) | 2001-07-13 | 2009-03-16 | 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536847A JP2004536847A (ja) | 2004-12-09 |
| JP2004536847A5 true JP2004536847A5 (https=) | 2006-01-05 |
Family
ID=32034390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003511808A Pending JP2004536847A (ja) | 2001-07-13 | 2002-07-15 | 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 |
| JP2009063664A Pending JP2009132738A (ja) | 2001-07-13 | 2009-03-16 | 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009063664A Pending JP2009132738A (ja) | 2001-07-13 | 2009-03-16 | 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1406600A4 (https=) |
| JP (2) | JP2004536847A (https=) |
| KR (1) | KR20040030042A (https=) |
| CN (1) | CN1527704B (https=) |
| CA (1) | CA2453442C (https=) |
| NZ (1) | NZ575466A (https=) |
| WO (1) | WO2003006002A1 (https=) |
| ZA (1) | ZA200400210B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229960A1 (en) * | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| JP4005048B2 (ja) * | 2003-04-09 | 2007-11-07 | 日信工業株式会社 | 炭素繊維複合材料およびその製造方法 |
| CA2766178A1 (en) * | 2009-07-02 | 2011-01-06 | Oxigene, Inc. | Combretastatins for prevention of posterior capsule opacification |
| WO2011022772A1 (en) | 2009-08-27 | 2011-03-03 | Bionomics Limited | Combination therapy for treating proliferative diseases |
| EP2470519B1 (en) * | 2009-08-27 | 2014-12-17 | Bionomics Limited | Treatment of macular degeneration |
| CN104619760B (zh) * | 2012-08-02 | 2016-10-26 | 阿米利尔股份公司 | 含纳米碳的天然橡胶 |
| CN113577020B (zh) * | 2021-08-16 | 2022-09-23 | 海南鑫开源医药科技有限公司 | 一种玻璃体腔内注射剂、其制备方法及应用 |
| CN113520995B (zh) * | 2021-08-16 | 2023-03-10 | 海南鑫开源医药科技有限公司 | 一种离子敏感型眼用原位凝胶、其制备方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338645C (en) * | 1987-01-06 | 1996-10-15 | George R. Pettit | Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins" |
| US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
| EP1045853B1 (en) * | 1998-01-09 | 2010-08-04 | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY | Synthesis of combretastatin a-4 prodrugs |
| GB9903404D0 (en) * | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
| WO2000048606A1 (en) * | 1999-02-18 | 2000-08-24 | Oxigene, Inc. | Compositions and methods for use in targeting vascular destruction |
| US6670344B2 (en) * | 2000-09-14 | 2003-12-30 | Bristol-Myers Squibb Company | Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts |
-
2002
- 2002-07-15 JP JP2003511808A patent/JP2004536847A/ja active Pending
- 2002-07-15 NZ NZ575466A patent/NZ575466A/en not_active IP Right Cessation
- 2002-07-15 CA CA2453442A patent/CA2453442C/en not_active Expired - Fee Related
- 2002-07-15 CN CN028139917A patent/CN1527704B/zh not_active Expired - Fee Related
- 2002-07-15 KR KR10-2004-7000464A patent/KR20040030042A/ko not_active Ceased
- 2002-07-15 EP EP02756487A patent/EP1406600A4/en not_active Withdrawn
- 2002-07-15 WO PCT/US2002/022449 patent/WO2003006002A1/en not_active Ceased
-
2004
- 2004-01-12 ZA ZA2004/00210A patent/ZA200400210B/en unknown
-
2009
- 2009-03-16 JP JP2009063664A patent/JP2009132738A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yadav et al. | Glaucoma: Current treatment and impact of advanced drug delivery systems | |
| Chaudhari et al. | Supramolecular cyclodextrin complex: Diversity, safety, and applications in ocular therapeutics | |
| TWI260327B (en) | Pharmaceutical compositions for treating ocular neovascular diseases | |
| TW539560B (en) | Ophthalmic drug delivery device | |
| AU2011282683B2 (en) | Preservative free brimonidine and timolol solutions | |
| EP2257275A2 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| TW200826977A (en) | Drug delivery device | |
| JP2006508120A5 (https=) | ||
| JP2018533629A (ja) | 眼障害を治療するためのプロテアソーム阻害剤の使用 | |
| JP2004536847A5 (https=) | ||
| RU2014151992A (ru) | Лечение воспалительных заболеваний глаз с применением лахинимода | |
| Kaith et al. | Pullulan as a sustained release carrier for ocular drug delivery: a review | |
| JP2023512583A (ja) | 予め活性化されたチオマーに基づく粘膜付着性の固体または半固体の眼用送達システム | |
| JP2011144111A (ja) | 軸性近視の予防または治療剤 | |
| CA2453442A1 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
| WO2010117077A1 (ja) | シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤 | |
| JP5735968B2 (ja) | 眼痛を処置または予防するためのケトロラクトロメタミン組成物 | |
| CN115634226B (zh) | 一种采用长春西汀治疗近视的方法 | |
| CN103432065B (zh) | 一种治疗青光眼的复合物凝胶及其制备方法 | |
| ZA200510344B (en) | Coumarin derivatives for the treatment of ophthalmic disorders | |
| TW201028176A (en) | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye | |
| RU2515550C1 (ru) | Способ лечения катаракты у больных с псевдоэксфолиативным синдромом | |
| HK40086794B (zh) | 一种采用长春西汀治疗近视的方法 | |
| RU2004104337A (ru) | Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний | |
| HK40086794A (zh) | 一种采用长春西汀治疗近视的方法 |